Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study explored peripheral blood immune dysregulation in alopecia areata through single-cell analyses, identifying systemic changes linked to disease severity and key signaling roles for monocytes, NK cells, and memory T cells, suggesting potential therapeutic targets.

In this study using the C3H/HeJ mouse model of alopecia areata, researchers found that hyperexpanded CD8⁺ T cell clones were sufficient to initiate disease, establishing a causal link between T cell clonality and pathogenicity.

This study systematically compared pediatric and adult Cushing's disease patients, revealing more severe and earlier-onset symptoms in males, and distinct gender-specific clinical manifestations.

This review discusses recent advances in understanding alopecia areata's disease mechanisms and highlights JAK molecules as promising therapeutic targets, but reports no new clinical results; controlled trials are needed.

This study found that in mice with alopecia areata, CD8+ T cells showed clonal expansion and specific regulatory networks, which might help identify new therapeutic targets for patients not responding to JAK inhibitors.

Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.

This article reviews the epidemiology, clinical evaluation, and pathogenesis of alopecia areata and highlights recent advancements, but it does not report new clinical findings.

This review discusses the role of regulatory T cells in skin, including their impact on hair follicle regeneration, wound healing, and immune tolerance, without presenting new clinical findings.

This review explores animal models of alopecia areata, particularly focusing on the insights they've provided into the disease's immune mechanisms and potential treatment approaches, without reporting new experimental data.

In this study, the researchers found that treatment with the JAK inhibitor tofacitinib in alopecia areata patients may reduce clonal CD8+ T cell expansions but does not eliminate them entirely, which could contribute to disease relapse.

This study observed that Epigallocatechin-3-gallate (EGCG) can inhibit phosphorylation of STAT1 and reduce a specific subset of immune cells in vitro and ex vivo, suggesting a potential role in maintaining immune privilege in alopecia areata.

In this study, researchers prepared a humanized CXCL12 antibody for alopecia areata treatment, finding it significantly delayed disease onset in mice and reduced immune cell activation, suggesting potential as an immune modulatory therapy.

In this narrative review, researchers outlined the role of T cells in the autoimmune pathogenesis of alopecia areata and highlighted ongoing research into therapeutic pathways, beyond current JAK inhibitors, aimed at developing new treatments for the disease.

In this clinical trial, patients with lichen planopilaris treated with the oral TYK2 inhibitor deucravacitinib showed significant improvement in PGA, LPPAI, and Skindex-16 scores over 24 weeks, with transcriptomic analyses indicating decreased inflammatory and immune pathway activity post-treatment.

This study demonstrated that disrupting EGFR signaling in mice leads to immune sensitivity compromising the hair follicle's protective environment, but JAK1/2 inhibition can restore this immune privilege and stimulate hair growth, suggesting a potential therapy for scarring hair loss diseases like cicatricial alopecia.

This case study reports a rare co-occurrence of alopecia areata and vitiligo in a 13-year-old female, suggesting a potential pathogenic link between the two autoimmune skin diseases.

This study found that treatment with PTH-CBD stimulated hair growth in mice with alopecia areata, with increased levels of beta catenin indicating activation of the Wnt pathway.

This review discusses the pathophysiology of alopecia areata, highlighting the role of CD8 cytotoxic T cells and the upregulation of JAK signaling pathways; it reports no new experimental results.

In this study, researchers found that hair follicle stem cells activate an immune-modulatory program during wound healing, promoting Treg cell expansion and aiding skin repair, while deleting certain immune components impaired healing and increased inflammation in a mouse model.

This case report describes the first known instance of fixed drug eruption linked to finasteride, confirmed through an oral challenge test that reproduced symptoms at the same skin site.

This study found that NK and CD8+ T cell infiltration may drive inflammation in androgenetic alopecia, suggesting that targeting IL-15 signaling could offer a new therapeutic approach for hair regeneration.

This review discusses the latest findings presented at the 4th Intercontinental Meeting of Hair Research Societies, covering advances in hair follicle biology, genetic bases for hair disorders, and potential new therapeutic approaches, but it reports no original study results.

In this study, researchers found that the cell surface protein Lrig1 plays a crucial role in regulating the suppressive function of regulatory T cells, suggesting it as a potential target for treating autoimmune diseases, as evidenced by experiments in mouse models.

This study found that patients with alopecia areata exhibited increased CRHR1 expression on circulating monocytes compared to controls, suggesting that stress-related factors like CRH and CRHR1 may contribute to the development and progression of the condition, particularly in chronic cases and those with larger lesions.

In this study, researchers found that serum granulysin levels might serve as a novel marker for disease activity in acute alopecia areata, being significantly associated with broader bald skin areas, poorer prognosis, and co-existing allergic disorders.

This study suggests that allogenic human mesenchymal stem cell treatments have potential therapeutic effects by inducing immune tolerance and anti-inflammatory effects in severe alopecia areata patients.

This study found that local injections of interleukin-4 and neutralizing anti-interferon-γ antibody effectively treated alopecia in a mouse model, suggesting potential therapeutic pathways for human alopecia areata.

Gut microbiota influences the development of alopecia areata.

This study found that pro-inflammatory cytokines and apoptotic mechanisms, specifically involving granzyme B and Fas pathways, are associated with chronic alopecia areata, indicating their potential role in the disease's persistence.

This case study reports that a combination of PUVA therapy and oral methyl prednisolone initially improved symptoms of a woman's cutaneous T-cell lymphoma but required ongoing treatment due to recurrence.